Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia

Br J Urol. 1993 Apr;71(4):433-8. doi: 10.1111/j.1464-410x.1993.tb15988.x.


We report the results of a prospective study with the pollen extract, Cernilton N, in a dose of 1 tablet tid for 6 months for the treatment of chronic prostatitis syndrome in 90 patients. The factors documented before and after 3 and 6 months' treatment were digital rectal examination (DRE) of the prostate, uroflowmetry, bacterial studies, leucocyte counts in urine and measurement of complement C3/coeruloplasmin in the seminal fluid. The patients were divided into 2 groups: those without associated complicating factors (CFs) (n = 72) and those with complicating factors, i.e. urethral strictures, prostatic calculi, bladder neck sclerosis (n = 18). In the group without CFs, 56 (78%) had a favorable response; 26 (36%) were cured of their symptoms and signs and 30 (42%) improved significantly with an increase in flow rate, a reduction in leukocyturia in the post-prostate massage urine (VB3) and a decrease in complement C3/coeruloplasmin in the ejaculate. In the patients with CFs only 1 patient showed a response. Complicating factors should be considered in patients who fail to respond to treatment within 3 months. Cernilton N was well tolerated by 97% of patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Ceruloplasmin / analysis
  • Chronic Disease
  • Complement C3 / chemistry
  • Humans
  • Leukocyte Count
  • Leukopenia / etiology
  • Male
  • Middle Aged
  • Pain / drug therapy*
  • Plant Extracts / therapeutic use*
  • Prospective Studies
  • Prostatitis / complications
  • Prostatitis / drug therapy*
  • Prostatitis / physiopathology
  • Rheology
  • Secale
  • Treatment Outcome
  • Urination
  • Urodynamics


  • Complement C3
  • Plant Extracts
  • cernilton
  • Ceruloplasmin